BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 34470666)

  • 41. Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level.
    Macartney-Coxson DP; Hood KA; Shi HJ; Ward T; Wiles A; O'Connor R; Hall DA; Lea RA; Royds JA; Stubbs RS; Rooker S
    BMC Cancer; 2008 Jul; 8():187. PubMed ID: 18590575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain.
    Stange DE; Engel F; Longerich T; Koo BK; Koch M; Delhomme N; Aigner M; Toedt G; Schirmacher P; Lichter P; Weitz J; Radlwimmer B
    Gut; 2010 Sep; 59(9):1236-44. PubMed ID: 20479215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
    Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
    Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.
    Khan M; Loree JM; Advani SM; Ning J; Li W; Pereira AAL; Lam M; Raghav K; Morris VK; Broaddus R; Maru D; Overman MJ; Kopetz S
    Clin Colorectal Cancer; 2018 Dec; 17(4):e699-e709. PubMed ID: 30205948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.
    Nash GM; Gimbel M; Shia J; Nathanson DR; Ndubuisi MI; Zeng ZS; Kemeny N; Paty PB
    Ann Surg Oncol; 2010 Feb; 17(2):572-8. PubMed ID: 19727962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
    Piskol R; Huw L; Sergin I; Kljin C; Modrusan Z; Kim D; Kljavin N; Tam R; Patel R; Burton J; Penuel E; Qu X; Koeppen H; Sumiyoshi T; de Sauvage F; Lackner MR; de Sousa E Melo F; Kabbarah O
    Clin Cancer Res; 2019 Jul; 25(14):4431-4442. PubMed ID: 31004000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer.
    Michl M; Taverna F; Kumbrink J; Schiergens TS; Heinemann V; Engel J; Kirchner T; Neumann J
    Virchows Arch; 2021 Apr; 478(4):695-705. PubMed ID: 33300106
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
    Thysell E; Köhn L; Semenas J; Järemo H; Freyhult E; Lundholm M; Thellenberg Karlsson C; Damber JE; Widmark A; Crnalic S; Josefsson A; Welén K; Nilsson RJA; Bergh A; Wikström P
    Mol Oncol; 2022 Feb; 16(4):846-859. PubMed ID: 34889043
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1.
    Ji D; Chen Z; Li M; Zhan T; Yao Y; Zhang Z; Xi J; Yan L; Gu J
    Mol Cancer; 2014 Apr; 13():86. PubMed ID: 24755295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis.
    Pizzini S; Bisognin A; Mandruzzato S; Biasiolo M; Facciolli A; Perilli L; Rossi E; Esposito G; Rugge M; Pilati P; Mocellin S; Nitti D; Bortoluzzi S; Zanovello P
    BMC Genomics; 2013 Aug; 14():589. PubMed ID: 23987127
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
    Goey KKH; Sørbye H; Glimelius B; Adams RA; André T; Arnold D; Berlin JD; Bodoky G; de Gramont A; Díaz-Rubio E; Eng C; Falcone A; Grothey A; Heinemann V; Hochster HS; Kaplan RS; Kopetz S; Labianca R; Lieu CH; Meropol NJ; Price TJ; Schilsky RL; Schmoll HJ; Shacham-Shmueli E; Shi Q; Sobrero AF; Souglakos J; Van Cutsem E; Zalcberg J; van Oijen MGH; Punt CJA; Koopman M
    Eur J Cancer; 2018 Sep; 100():35-45. PubMed ID: 29936065
    [TBL] [Abstract][Full Text] [Related]  

  • 55. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases.
    Gentner B; Wein A; Croner RS; Zeittraeger I; Wirtz RM; Roedel F; Dimmler A; Dorlaque L; Hohenberger W; Hahn EG; Brueckl WM
    Anticancer Res; 2009 Jan; 29(1):67-74. PubMed ID: 19331134
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer.
    Jesinghaus M; Wolf T; Pfarr N; Muckenhuber A; Ahadova A; Warth A; Goeppert B; Sers C; Kloor M; Endris V; Stenzinger A; Weichert W
    Am J Surg Pathol; 2015 Aug; 39(8):1140-7. PubMed ID: 25786087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refining colorectal cancer classification and clinical stratification through a single-cell atlas.
    Khaliq AM; Erdogan C; Kurt Z; Turgut SS; Grunvald MW; Rand T; Khare S; Borgia JA; Hayden DM; Pappas SG; Govekar HR; Kam AE; Reiser J; Turaga K; Radovich M; Zang Y; Qiu Y; Liu Y; Fishel ML; Turk A; Gupta V; Al-Sabti R; Subramanian J; Kuzel TM; Sadanandam A; Waldron L; Hussain A; Saleem M; El-Rayes B; Salahudeen AA; Masood A
    Genome Biol; 2022 May; 23(1):113. PubMed ID: 35538548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore.
    Baldin P; Van den Eynde M; Mlecnik B; Bindea G; Beniuga G; Carrasco J; Haicheur N; Marliot F; Lafontaine L; Fredriksen T; Lanthier N; Hubert C; Navez B; Huyghe N; Pagès F; Jouret-Mourin A; Galon J; Komuta M
    J Pathol Clin Res; 2021 Jan; 7(1):27-41. PubMed ID: 32902189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.